Overcoming the BCG Shortage With TARA-002 for High-Grade NMIBC

Neal Shore, MD, FACS, Carolina Urologic Research Center, gives an overview of the investigational drug TARA-002 for high-grade non-muscle invasive bladder cancer and how the treatment can potentially aid patients during the ongoing BCG shortage. He elaborates on how TARA-002 differs from existing therapies, and how it might influence the treatment landscape for both BCG-naive and BCG-unresponsive patients.